IJCCR_2024v14n5

International Journal of Clinical Case Reports 2024, Vol.14, No.5, 230-241 http://medscipublisher.com/index.php/ijccr 241 Tojjari A., Saeed A., Singh M., Cavalcante L., Sahin I., and Saeed A., 2023, A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma, Vaccines, 11(8): 1357. https://doi.org/10.3390/vaccines11081357 PMID: 37631925 PMCID: PMC10459477 Tay R.E., Richardson E.K., and Toh H.C., 2021, Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms, Cancer Gene Ther, 28(1-2): 5-17. https://doi.org/10.1038/s41417-020-0183-x PMID: 32457487 PMCID: PMC7886651 Wang M., Cao J., Liu Y., Xu B., Li D., Zhang X., Li J., Liu J., Wang H., and Wang Z., 2015, Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis, BMJ Open, 5(4): e006321. https://doi.org/10.1136/bmjopen-2014-006321 PMID: 25872936 PMCID: PMC4401843 Wu Q., Wang Q., Tang X., Xu R., Zhang L., Chen X., Xue Q., Wang Z., Shi R., Wang F., Ju F., Zhang B., and Zhou Y., 2019, Correlation between patients' age and cancer immunotherapy efficacy, OncoImmunology, 8(4): e1568810. https://doi.org/10.1080/2162402X.2019.1568810 PMID: 30906662 PMCID: PMC6422380 Widman A., Cohen B., Park V., McClure T., Wolchok J., and Kamboj M., 2022, Immune-related adverse events among COVID-19-vaccinated patients with cancer receiving immune checkpoint blockade, Journal of the National Comprehensive Cancer Network : JNCCN, 20(10): 1134-1138. https://doi.org/10.6004/jnccn.2022.7048 PMID: 36240845 PMCID: PMC10975484 Wang T., 2024, The application prospects of immunomodulators in cancer treatment, Cancer Genetics and Epigenetics, 12(1): 1-7. https://doi.org/10.5376/cge.2024.12.0001 Xu C., Chen Y., Du X., Liu J., Huang C., Chen L., Zhou G., Li W., Mao Y., Hsu C., Liu Q., Lin A., Tang L., Sun Y., and Ma J., 2018, Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis, The BMJ, 363: k4226. https://doi.org/10.1136/bmj.k4226 PMID: 30409774 PMCID: PMC6222274 Yang F., Wang Y., Nowakowski G., Wang M., Chintakuntlawar A., Halfdanarson T., Pagliaro L., Wei J., Liu B., Molina J., and Markovic S., 2019, Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials, Journal of Clinical Oncology, 3(8): e2012534. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.6592 PMID: 32766800 PMCID: PMC7414387 Yan X., Tian X., Wu Z., and Han W., 2020, Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis, Frontiers in Oncology, 10: 1671. https://doi.org/10.3389/fonc.2020.01671 PMID: 33072551 PMCID: PMC7538697 Zhao J., Chen Y., Ding Z., and Liu J., 2019, Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment, Frontiers in Pharmacology, 10: 1184. https://doi.org/10.3389/fphar.2019.01184

RkJQdWJsaXNoZXIy MjQ4ODYzNQ==